Radioimmunotherapy as Treatment for AML

Video

Joseph Jurcic, MD, head, Hematologic Malignancies, Columbia University Medical Center, discusses using radioimmunotherapy as a treatment option for patients with AML.

Joseph Jurcic, MD, head, Hematologic Malignancies, Columbia University Medical Center, discusses using radioimmunotherapy as a treatment option for patients with AML.

Clinical Pearls

  • Only 40% of patients with AML under the age of 60 are cured while only 10% of patients over the age of 60 are cured. The median survival is approximately 6 months.
  • Radioimmunotherapy is one way that physicians can help develop more effective therapies while reducing toxicity.
  • Initial studies used a beta-emitter but now physicians use alpha particles in therapy.
  • By using alpha particles, physicians are able to target the tumor cell and do less damage to the surrounding normal tissue.

<<<

More from "Immunotherapy News from ASCO"

Related Videos
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Jamie Koprivnikar, MD, and Hana Safah, MD, experts on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Related Content